Velsera’s Post

My journey at Seven Bridges (now Velsera) started with being the program manager for the SPARK platform for PanCAN, in 2021. Working with the Pancreatic Cancer Action Network data science and informatics team, under the fierce leadership from Kawther Abdilleh has been a pleasure! I can't wait to see what our teams do together in the coming years! Go read the research paper here: https://lnkd.in/gDc2F2X3 and ping me if you have any questions... let's improve the health of pancreatic cancer patients, together. #precisionmedicine #clinicalresearch #bioinformatics

We are excited to announce that stakeholders strongly supported Health-RI’s position as the national cancer research data node in the Netherlands. 🎉   This milestone marks a significant step forward in our mission to advance cancer research and improve patient outcomes though data-driven insights. As we move forward, we're eager to crystalize the functionality of the node, aligning with our plateau planning and strategy across clinical domains, extending beyond oncology to other diease domains, such as cardiovascular disease, rare diseases and so forth.   A special thanks to IKNL (Integraal Kankercentrum Nederland) for hosting the recent session and for Gijs Geleijnse’s role as our co-chair of the node. Together, we're making strides in enhancing visibility and importance within the cancer data research community.    Stay tuned for more updates as we continue our journey towards innovation and excellence in cancer research!   You are welcome to join our node by contacting the node coordinator, Lifang Liu ( lifang.liu@health-ri.nl), and look forward seeing you in the next node meeting in the fall. Read more and see all visuals/designs: https://lnkd.in/e7TnDP7i   #CancerResearch #DataNode #Collaboration #Innovation #FAIR #FAIRdata #Healthcare #EHDS #europeanhealthdataspace #healthdata #secondaryuse

Cancer continuously proves to be a complicated, multi-faceted disease, and while research breakthroughs are improving outcomes for patients, equity in access to these breakthroughs remains a challenge. This year, #WorldCancerResearchDay 2024 has aptly focused on bridging gaps in care through the theme “Innovation in Cancer Research Drives Progress Toward Health Equity.” In line with this, I want to highlight the pivotal role of our talented Medical Science Liaisons (MSLs), who act as key facilitators of innovative research. Their work ensures that groundbreaking advancements reach the healthcare providers and patients who need them most. MSLs engage with healthcare providers in a precise, tailored way, translating cutting-edge research into real-world solutions. By fostering trust and collaboration with oncologists, MSLs help ensure that patients from all backgrounds can receive personalized, high-quality care based on the latest scientific developments. Their strategic engagements enable healthcare teams to apply the most advanced treatments in a way that is relevant to each patient’s unique needs. This direct connection to the World Cancer Research Day message is clear – while innovation drives progress, it’s the work of skilled communicators like MSLs that ensure these advancements reach all patients, contributing to greater health equity. Following an exciting past few weeks between WCLC, ESMO, and now World Cancer Research Day, thank you to the MSLs who conduct this critical work. You are driving both #innovation and #equity in our efforts to eliminate cancer as a cause of death. #OncologyCare #MSLImpact #CancerResearch #HealthEquity #PrecisionMedicine

🌍 Celebrating World Cancer Research Day 2024: Driving Progress Toward Health Equity🎗️ At #Cefea, we are proud to join the global community in recognizing World Cancer Research Day 2024, a day dedicated to celebrating innovation in the fight against cancer. This year's theme, "Innovation In Cancer Research Drives Progress Toward Health Equity," underscores the critical role that breakthroughs in cancer care play in leveling the healthcare playing field. From prevention to treatment, the advancements in research are not just improving survival rates—they are bringing life-changing care to more patients around the world. With the support of forward-thinking policies and cutting-edge technology, we are moving closer to a future where health equity in cancer treatment is a reality for everyone, no matter their location or circumstances. On this day, let’s recognize the incredible contributions of researchers and advocates who are pushing boundaries to improve patient outcomes and save lives. Together, we are driving progress that will make a lasting impact on health equity worldwide. #WorldCancerResearchDay #CancerResearch #Innovation #HealthEquity #Cefea #CancerPrevention #CancerTreatment #GlobalHealth #ResearchForAll

🚀 Proud to share! The whitepaper “Good Practices in Lung Cancer Multi-Disciplinary Teams (MDTs)” has been released as part of the MDT Aid Program (MAP). This achievement marks the culmination of extensive MAP efforts across the US, Europe, Canada and China, providing hospitals with innovative tools and strategies to improve MDT-based lung cancer care.   🌟 MAP, a collaborative creation by our Commercial Digital Health team regional and in-country teams, aims to standardize MDTs and enhance their efficiency. While MDTs are essential in cancer care, disparities in access, processes and technology persist. Our aim is to define and implement best practices, supporting hospitals in adopting cutting-edge solutions worldwide.   👏 Cheers to my AstraZeneca co-authors Heather Moses, Adrien Moucquot, S. Hassan N., María Teresa Campos, and our Vintura partners.. We also extend gratitude to the numerous co-authors and endorsing healthcare institutions. Your contributions are pivotal in the ongoing success of MAP and its positive impact on global patient care.    https://lnkd.in/er7dspAC #LungCancer #MDTAidProgram #HealthcareInnovation #collectiveintelligence

🩺 On this World Cancer Day, let's embrace a future where hope and science coalesce to transform the cancer narrative. #WorldCancerDay2024 The burden of cancer is mounting, with a predicted 77% surge in cases by 2050. But amidst these stark statistics lies a beacon of innovation: omics technologies and personalized treatments. These advancements are not mere concepts; they're revolutionizing cancer care today, offering a tailored approach to each unique genetic story. 🧬 As we navigate through this era of precision oncology, we're reminded of the power of machine learning, dissecting complex data to advance diagnosis, prognosis, and treatment. The synergy of technology and medical expertise is creating a new paradigm of care - one that's predictive, preventative, and profoundly personal. But let's not forget: access to such transformative care is a right, not a privilege. Ensuring every patient benefits from these scientific strides is a collective responsibility. Let's stand together this World Cancer Day to advocate for equitable health solutions and to celebrate the promise of a future where every cancer journey is as unique as the individual embarking on it. For those seeking to navigate the complexities of omics data, aimed analytics is here to offer comprehensive analyses, propelling personalized treatment strategies into the forefront of patient care. 🎯 Let's harness the potential of precision medicine together. #CancerCare #OmicsTechnology #PersonalizedMedicine #MachineLearning

🌍 INNOVATION: THE ONCOSCREEN PROJECT🌍 We are excited about the advancement of the ONCOSCREEN project, which aims to transform the way colorectal cancer is screened and diagnosed in Europe. 🚀 How does it work? 🔬Comprehensive validation: The tools developed will be tested extensively in clinical trials, with the participation of 4,100 citizens and patients from 10 European countries. 🧑🏻🤝🧑🏽 Participatory approach: ONCOSCREEN will incorporate the opinions and perspectives of citizens and patients through a participatory co-design method, coupled with open innovations and FAIR (Findable, Accessible, Interoperable, and Reusable) data. 🎯 End goal: The end goal is for these innovative solutions to be adopted by public health systems and in daily clinical practice across Europe. ONCOSCREEN’S mission is to make bowel cancer screening more accessible and effective for everyone. Join us on this journey to improve the detection and treatment of digestive cancers in Europe! 🌟 https://oncoscreen.health/   #ONCOSCREEN #Innovation #Europe #CRC #EarlyDiagnose #ColorectalCancer #EUCancer

Ovarian Cancer Research Alliance's Health Equity Research Grants for 2024 are dedicated to advancing equity in the care of ovarian and related gynecologic cancers — addressing deep disparities in early diagnosis, access to care, and patient outcomes.  Dr. Emily Ko of University of Pennsylvania — recipient of OCRA's Health Equity Research Grant, Sponsored by GSK — is focused on addressing practical barriers to receiving optimal care.  OCRA's Health Equity Research Grant recipients Dr. David Shalowitz of West Michigan Cancer Center and Dr. Judith Walsh of University of California, San Francisco are focused, respectively, on increasing access to high-quality care for patients in remote areas and reducing disparities in ovarian cancer early diagnosis. Learn more about their projects at bit.ly/3Kg2k2y. #OvarianCancer #HealthEquity #CancerResearch

🌍 INNOVATION: THE ONCOSCREEN PROJECT🌍   We are excited about the advancement of the ONCOSCREEN project, which aims to transform the way colorectal cancer is screened and diagnosed in Europe. 🚀   How does it work? 🔬Comprehensive validation: The tools developed will be tested extensively in clinical trials, with the participation of 4,100 citizens and patients from 10 European countries.   🧑🏻🤝🧑🏽 Participatory approach: ONCOSCREEN will incorporate the opinions and perspectives of citizens and patients through a participatory co-design method, coupled with open innovations and FAIR (Findable, Accessible, Interoperable, and Reusable) data.   🎯 End goal: The end goal is for these innovative solutions to be adopted by public health systems and in daily clinical practice across Europe. ONCOSCREEN’S mission is to make bowel cancer screening more accessible and effective for everyone.   Join us on this journey to improve the detection and treatment of digestive cancers in Europe! 🌟   #ONCOSCREEN #Innovation #Europe #CRC #EarlyDiagnose #ColorectalCancer #EUCancer

🌍 INNOVATION: THE ONCOSCREEN PROJECT🌍   We are excited about the advancement of the ONCOSCREEN project, which aims to transform the way colorectal cancer is screened and diagnosed in Europe. 🚀   How does it work? 🔬Comprehensive validation: The tools developed will be tested extensively in clinical trials, with the participation of 4,100 citizens and patients from 10 European countries.   🧑🏻🤝🧑🏽 Participatory approach: ONCOSCREEN will incorporate the opinions and perspectives of citizens and patients through a participatory co-design method, coupled with open innovations and FAIR (Findable, Accessible, Interoperable, and Reusable) data.   🎯 End goal: The end goal is for these innovative solutions to be adopted by public health systems and in daily clinical practice across Europe. ONCOSCREEN’S mission is to make bowel cancer screening more accessible and effective for everyone.   Join us on this journey to improve the detection and treatment of digestive cancers in Europe! 🌟   #ONCOSCREEN #Innovation #Europe #CRC #EarlyDiagnose #ColorectalCancer #EUCancer